Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trialJane C. Burns, Nichole Samuy, James B. Wood et al.|The Lancet Child & Adolescent Health|2021Cited by 113
Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United StatesJennifer Burney, Archana Chatterjee, Samantha C. Roberts et al.|JAMA Network Open|2022Cited by 52
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C. Roberts, Sylvia H. Yeh, Sonia Jain et al.|Contemporary Clinical Trials|2019Cited by 25
Multicentre validation of a computer-based tool for differentiation of acute Kawasaki disease from clinically similar febrile illnessesShiying Hao, Adriana H. Tremoulet, Xuefeng B. Ling et al.|Archives of Disease in Childhood|2020Cited by 14
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C. Roberts, Sylvia H. Yeh, Sonia Jain et al.|Author eBooks|2019Cited by 1